You are here

Recent Pfizer Press Releases

6/28/16 8:30am EDT
Two Additional Phase 3 Lipid-Lowering Studies of Bococizumab Deliver Positive Topline Results

SPIRE-HR and SPIRE-FH trials met primary endpoints in patients at high and very high risk for cardiovascular events

Pfizer Inc.

more...
6/27/16 11:30pm EDT
Pfizer Advances Biosimilars Leadership with Investment in a New World-Class Global Biotechnology Center in China

Pfizer’s state-of-the-art facility will foster the continued development of the biotechnology industry in China, further supporting National healthcare reforms

Pfizer Inc. today announced that it will invest approximately USD$350 million in the development of a state-of-the-art Global Biotechnology Center at a ground-breaking ceremony in the Hangzhou Economic Development Area (HEDA) in China.

more...
6/24/16 9:00am EDT
Pfizer Completes Acquisition of Anacor

Tender offer for all of the outstanding shares of Anacor common stock expired as scheduled immediately after 11:59 p.m., New York City time, on June 23, 2016

Pfizer and Anacor begin joint operations on June 24, 2016

Pfizer Inc. (NYSE:PFE) today announced that it has completed its acquisition of Anacor Pharmaceuticals, Inc. Under the terms of the transaction, each outstanding share of Anacor common stock has been converted into the right to receive $99.25 net in cash (without interest but subject to required withholding of taxes).

more...
6/23/16 4:00pm EDT
Pfizer Declares 30-Cent Third-Quarter 2016 Dividend

The board of directors of Pfizer Inc. today declared a 30-cent third-quarter 2016 dividend on the company’s common stock, payable September 1, 2016, to shareholders of record at the close of business on August 5, 2016. The third-quarter 2016 cash dividend will be the 311th consecutive quarterly dividend paid by Pfizer.

Pfizer Inc.

more...
6/21/16 10:00am EDT
Pfizer Invites Public To View And Listen To Webcast Of August 2 Conference Call With Analysts

Pfizer Inc. invites investors and the general public to view and listen to a webcast of a conference call with investment analysts at 10 a.m. EDT on Tuesday, August 2, 2016. The purpose of the call is to provide an update on Pfizer’s results, as reflected in the company’s Second Quarter 2016 Performance Report, to be issued that morning.

more...
6/16/16 9:00am EDT
Help Pfizer Change The Future Of Healthy Aging

First-of-its-kind Partnership with Indiegogo Will Help Develop the Next Big Idea in Healthy Aging

Pfizer Inc. is challenging people across the United States (U.S.) to develop the next big idea in healthy aging through a unique partnership with crowdfunding platform Indiegogo.

more...
6/16/16 8:30am EDT
Pfizer Breaks Ground On New Biologics Clinical Manufacturing Facility In Andover, Massachusetts

Pfizer Inc. today broke ground for its new biologics clinical manufacturing facility in Andover, Massachusetts. Expanding the company’s presence in the state, Pfizer will invest more than $200 million in development of the 175,000 sq. ft. state-of-the-art facility that will enable the production of high-quality, complex biologics and vaccines.

more...
6/12/16 5:15am EDT
Pfizer Announces Final Results from Inotuzumab Ozogamicin Pivotal Phase 3 Study in Adults with Relapsed/Refractory Acute Lymphoblastic Leukemia

  • Results of INO-VATE ALL Trial Published in The New England Journal of Medicine
  • Overall Survival Data Also Presented as a Late-Breaking Oral Presentation at EHA 2016

Pfizer Inc.

more...
6/11/16 11:00am EDT
Merck and Pfizer Announce Two Pivotal Phase 3 Studies for Ertugliflozin, an Investigational SGLT-2 Inhibitor, Met Primary Endpoints, Showing Significant A1C Reductions in Patients with Type 2 Diabetes

  • Ongoing CV Outcomes Trial of Ertugliflozin Expanded to Test for Superiority in CV Risk Reduction 

Merck (NYSE:MRK), known as MSD outside the United States and Canada, in partnership with Pfizer Inc. (NYSE:PFE), today announced that two Phase 3 studies (VERTIS Mono and VERTIS Factorial) of ertugliflozin, an investigational oral SGLT-2 inhibitor for the treatment of patients with type 2 diabetes, met their primary endpoints. The study results showed statistically significant reductions in A1C (a measure of average blood glucose) for both ertugliflozin doses tested (5 mg and 15 mg daily).

more...
6/9/16 7:30am EDT
Pro Golfer Jim Furyk Teams Up With Pfizer To Raise Awareness For Pneumococcal Pneumonia And The Importance Of Older Adult Vaccination

Furyk Takes Time to Coach His Coach, His Father, and Other Adults 65 and Older About the Risk for Potentially Serious Infectious Diseases, Like Pneumococcal Pneumonia

This Father’s Day, Jim Furyk will be thinking about more than just strategizing for the next Major as he joins Pfizer to encourage adults 65 and older to take responsibility for their health. On Father’s Day 2003, Furyk won a Major with his coach and father, Mike, by his side.1 This year, Jim will be one of 156 golfers to gather in Oakmont, PA, to play in one of professional golf’s major championship tournaments.

more...
6/8/16 7:15pm EDT
Pfizer Announces FDA Advisory Committees’ Recommend ALO-02 (oxycodone hydrochloride and naltrexone hydrochloride) Extended-Release Capsules for Approval

Pfizer Inc. (NYSE: PFE) announced today that the U.S. Food and Drug Administration (FDA) Anesthetic and Analgesic Drug Products Advisory Committee and Drug Safety and Risk Management Advisory Committee voted (9 to 6) in favor of approval of ALO-02 (oxycodone hydrochloride and naltrexone hydrochloride) extended-release capsules for its proposed indication, “management of pain severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate.”

more...
6/8/16 7:01am EDT
Pfizer Research Advances Body Of Evidence For Tofacitinib Citrate (XELJANZ®) Providing Clinicians With Additional Information For The Treatment Of Moderate to Severe RA

More Than 20 Abstracts will be Featured at the European League Against Rheumatism Annual Congress (EULAR 2016)
 

Pfizer Inc. (NYSE:PFE) announced today that 23 abstracts1, including research and analyses for tofacitinib citrate (XELJANZ®), will be featured at the upcoming European League Against Rheumatism (EULAR) Congress (June 8-11, London). The research being shared at the meeting provides new and additional information on the efficacy and safety profile of tofacitinib citrate, including its use as a single agent without methotrexate.

more...
6/7/16 10:00am EDT
A Mother’s Mission to Help Prevent Another Life Lost to MenB

The Kimberly Coffey Foundation and Pfizer Partner on National Meningococcal Disease Awareness Survey to Highlight Gap in MenB Knowledge Among Parents

One moment Patti Wukovits was preparing for her daughter’s high school graduation, and the next moment she was watching her fight for her life for 9 days in the intensive care unit. In 2012, Patti lost her 17-year-old daughter, Kimberly Coffey, to group B meningococcal disease, also known as MenB, just days before Kim’s senior prom and high school graduation.

more...
6/7/16 7:00am EDT
Pfizer Announces Positive Top-Line Results from Second Phase 3 Trial of Oral XELJANZ® (Tofacitinib Citrate) in Adults with Psoriatic Arthritis

Pfizer Inc. (NYSE:PFE) announced today top-line results from Oral Psoriatic Arthritis triaL (OPAL) Beyond, the second Phase 3 study of XELJANZ® (tofacitinib citrate) being investigated in patients with active psoriatic arthritis (PsA).

more...
6/6/16 9:00am EDT
ASCO 2016: Pivotal Avelumab Study Shows Positive Results in Metastatic Merkel Cell Carcinoma

•First pivotal study for Merck KGaA, Darmstadt, Germany, and Pfizer’s investigational anti-PD-L1 antibody avelumab shows clinically meaningful tumor responses in pre-treated metastatic Merkel cell carcinoma (MCC)
•International, multicenter Phase II study results in metastatic MCC with 88 patients represents largest data set of any anti-PD-L1/PD-1 reported in this patient population
•Plan to submit to regulatory authorities based on these results
 

Merck KGaA, Darmstadt, Germany, and Pfizer (NYSE: PFE) today announced results from the first pivotal, international, multicenter, open-label, Phase II study of avelumab*, which showed a 31.8% objective response rate (ORR) (28 of 88 patients; 95.9% CI: 21.9–43.1%), in the pre-planned primary analysis of the study, and a manageable safety profile in patients with metastatic Merkel cell carcinoma (MCC) who were treated with avelumab in second or subsequent lines of therapy.

more...
6/6/16 8:00am EDT
Pfizer Presents Promising Data from Next Generation ALK/ROS1 Inhibitor in Advanced Non-Small Cell Lung Cancer

Study Results Presented as Oral Abstract at ASCO 2016

Pfizer Inc. (NYSE:PFE) today announced encouraging new data from a Phase 1/2 study of lorlatinib, the proposed generic name for PF-06463922, Pfizer’s investigational, next-generation ALK/ROS1 tyrosine kinase inhibitor. The study showed clinical response in patients with ALK-positive or ROS1-positive advanced non-small cell lung cancer (NSCLC), including patients with brain metastases. These data were presented today in an oral presentation at the 52nd Annual Meeting of the American Society of Clinical Oncology (ASCO) in Chicago.

more...
6/4/16 8:00am EDT
Pfizer Presents Data from Phase 1b Trial Investigating Utomilumab (a 4-1BB agonist) in Combination with a Checkpoint Inhibitor

Oral ASCO Presentation Shows Encouraging Safety Data and Increased Support for Novel Immunotherapy Combinations

Pfizer Inc. (NYSE:PFE) today announced results from a Phase 1b trial of Pfizer’s investigational immunotherapy agent utomilumab (the proposed non-proprietary name for PF-05082566), a 4-1BB (also called CD137) agonist, in combination with pembrolizumab, a PD-1 inhibitor, in patients with advanced solid tumors. This is the first reported study of a 4-1BB agonist combined with a checkpoint inhibitor. Encouraging safety data from the study were shared today as an oral presentation at the 52nd Annual Meeting of the American Society of Clinical Oncology (ASCO) in Chicago.

more...
5/26/16 10:38am EDT
Pfizer Invites Public to Listen to Webcast of Pfizer Discussion at Healthcare Conference

Pfizer Inc. invites investors and the general public to listen to a webcast of a discussion with Ian Read, Chairman and Chief Executive Officer, at the Bernstein 32nd Annual Strategic Decisions Conference on Thursday, June 2, 2016 at 2:00 p.m. Eastern Daylight Time.

more...
5/23/16 7:00am EDT
CHAMPIX® (varenicline) European Union Label Updated to Include New Safety and Efficacy Data from the EAGLES Clinical Trial Following Endorsement from CHMP

Black triangle indicating additional safety monitoring requirement for CHAMPIX in the EU has been removed

 

 

more...
5/20/16 8:00am EDT
Pfizer Announces European Medicines Agency Acceptance for Review of Marketing Authorization Application for TRUMENBA® (Meningococcal Group B Vaccine)

Pfizer Inc. (NYSE:PFE) today announced the European Medicines Agency (EMA) has accepted the Marketing Authorization Application (MAA) for TRUMENBA® (Meningococcal Group B Vaccine) for review. TRUMENBA has been developed for the prevention of invasive meningococcal disease (IMD) caused by Neisseria meningitidis serogroup B (MnB) in individuals aged 10 years and older. The acceptance marks the beginning of the regulatory review process for this vaccine in the EU.

more...

Pages